A carregar...
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
BACKGROUND: Several large clinical trials have confirmed the cardioprotective role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes. However, whether empagliflozin, as an SGLT2i, could alleviate atherosclerosis progression in non-diabetic states remain unknown....
Na minha lista:
| Publicado no: | Lipids Health Dis |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7802233/ https://ncbi.nlm.nih.gov/pubmed/33436015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12944-021-01430-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|